TEKTURNA (aliskiren hemifumarate) · NODEN PHARMA
TEKTURNA is FDA-approved to treat 3 conditions (same as ALISKIREN HEMIFUMARATE).
Details
- Status
- Discontinued
- First Approved
- 2007-03-05
- Patent Cliff
- 2026
- Routes
- ORAL
- Dosage Forms
- CAPSULE, PELLET, TABLET
TEKTURNA Approval History
What TEKTURNA Treats
3 indicationsTEKTURNA is approved for 3 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.
Same approved indications as ALISKIREN HEMIFUMARATE (same active ingredient).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TEKTURNA FDA Label Details
Indications & Usage
FDA Label (PDF)TEKTURNA is FDA-approved to treat 3 conditions — same approved indications as ALISKIREN HEMIFUMARATE.
TEKTURNA Patents & Exclusivity
Patents (2 active)
Pro Intelligence Preview
Deep insights for TEKTURNA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2026
- • 8 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.